Averin Capital
Status
ACTIVE
Global HQ
New York, United States
Countries of investment
- United States
- United Kingdom
- Europe
- Asia
Investment stages
- Pre-Seed
- Seed
- Series A
- Series B
Industries
- Health Care
- AI
- Life Sciences
- Deep Tech
- Robotics
- Diagnostics
About
Averin Capital is a New York venture firm, formerly known by its Bedford Bridge fund name, that backs and builds companies transforming human health through AI and breakthrough technologies. It invests from pre-seed onward in the US, Europe and Asia.
Averin Capital is a New York venture firm, formerly known by its Bedford Bridge fund name, that backs and builds companies transforming human health through AI and breakthrough technologies. It invests from pre-seed onward in the US, Europe and Asia.
Investment Thesis
Averin Capital backs and builds early-stage companies where breakthrough technology is transforming human health, across foundational science, physical AI, care delivery, healthcare infrastructure and human performance. It invests from pre-seed through later stages in the United States, Europe and Asia, with initial checks of $500K to $10M, and sometimes leads rounds. Its team of physician-scientists and operators has founded or launched more than 30 companies, and team members have helped build, lead or back 22 companies now worth over $1B.
Manager's Experience
Founded in 2024 in New York by co-founders and Managing Partners David Berry and Eric Berry. The partnership combines physician-scientists and operators who have founded or launched more than 30 companies, and team members have helped build, lead or back 22 companies valued at over $1B. Funds include Bedford Bridge Fund I and Averin Capital Fund II.
Team
David Berry - CoFounder & Managing Partner
Eric Berry - CoFounder & Managing Partner
Tristan Hunt - Partner
Jeffrey Low - Partner
Tomer Zitelny - Partner
Alex Lau - Partner & Chief Operating Officer
Portfolio
Biolinq
Pine Park Health
Hologen AI
CandidPro
Freenome
Mendaera